Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?

Guo, Jianfeng; Bourré, Ludovic; Soden, Declan M.; O’Sullivan, Gerald C.; O’Driscoll, Caitriona M.

doi:10.1016/j.biotechadv.2011.03.003

Cited by 95 publications

(63 citation statements)

References 193 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the other hand, it is considered as the main cause of mortality and morbidity in women [1,2]. Current therapy methods of breast cancer such as surgery, radio therapy and chemotherapy improved survival of women suffering breast cancer [3]. Among chemotherapy agents, Hydroxyurea (HU) is commonly used as an anti-cancer agent [4].…”

Section: Introductionmentioning

confidence: 99%

In Vitro Evaluation of the Efficacy of Liposomal and Pegylated Liposomal Hydroxyurea

et al. 2013

View full text Add to dashboard Cite

Breast cancer is one of the most frequent cancer types within women population. Hydroxyurea (HU) is a chemotherapy compound for treatment of patients with cancer diagnosis, including breast cancer associated with several adverse effects. In this study, we applied nanotechnology to decreased drug side effects along with improvement of therapeutic index. Liposomation is widely used in modern pharmacological developments in order to enhance the effects of the drugs. To achieve this, in this study a mixture of phosphatidylcholine and cholesterol was made up and HU was added to the resultant mixture, was then pegylated using Polyethylene Glycol 2000 to increase resistance, applicability and solubility. The mean diameters of nanoliposomal and pegylated nanoliposomal HU were measured by Zeta sizer device and obtained about 402.5 and 338.2 nm. The efficiency of non-pegylated and pegylated liposomal HU was 70.8 and 64.2, respectively. Releasing HU in both formulations was estimated about 25.8 and 21.7 %. Also, this study investigated the cytotoxicity effect of nanoliposomal and pegylated nanoliposomal HU using MTT assay. Results of this investigation showed that the cytotoxic properties of pegylated HU was 3.6 % more than those non-pegylated form, while was 38.93 % more than ordinary from of HU. This study showed that the stability, releasing pattern and cytotoxicity of the pegylated nanoliposomal HU is better than that of nanoliposomal HU.

show abstract

Section: Introductionmentioning

confidence: 99%

In Vitro Evaluation of the Efficacy of Liposomal and Pegylated Liposomal Hydroxyurea

et al. 2013

View full text Add to dashboard Cite

show abstract

“…This implies that following systemic administration non-specific binding of serum proteins onto AuNP formulations may occur causing particle aggregation and subsequent clearance by the mononuclear phagocytic system [MPS, also known as the reticuloendothelial system (RES)]. This phenomenon known as opsonisation results in a short in vivo half-life [51]. One of the most widely studied approaches to avoid RES uptake is the addition of a PEG moiety to form so called 'stealth' particles [52].…”

Section: Endogenous Gene Silencing Of Folic Acid-conjugated Nanopartimentioning

confidence: 99%

Bioconjugated gold nanoparticles enhance cellular uptake: A proof of concept study for siRNA delivery in prostate cancer cells

Guo

O’Driscoll

Holmes

et al. 2016

International Journal of Pharmaceutics

Self Cite

View full text Add to dashboard Cite

“…One of the drugs used in cancer treatment is artemisinin which is a lactone taken from the leaves of Artemisia annua [7,8]. Artemisinin molecule causes molecular damage and ultimately makes the cells die [7,9].…”

Section: Introductionmentioning

confidence: 99%

Study of Toxicity Effect of Pegylated Nanoliposomal Artemisinin on Breast Cancer Cell Line

et al. 2013

View full text Add to dashboard Cite

Nano carriers have greatly revolutionized the treatment of most diseases recently. One of these nano carriers, liposomes, has got particular significance. On the other hand, Artemisinin which is used as an effective anticancer drug has some side effects. To reduce such side effects, liposomes can be employed. In order to prepare pegylated nanoliposomal artemisinin, particular proportions of phosphatidylcholine, polyethylene glycol 2000 and artemisinin were combined. As a result, the mean diameter of nano liposomes is 455 nm. Besides, the encapsulation efficiency and the drug release from pegylated nanoliposomes for pegylated nanoliposomal artemisinin are respectively 91.62 ± 3.5 and 5.17 %. The results also show that IC50 of the produced formulation is less than that of the standard drug. This study reveals that the amount of artemisinin cytotoxicity compared to standard drug is increased by pegylated nanoliposomal formulation.

show abstract

Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics?

Cited by 95 publications

References 193 publications

In Vitro Evaluation of the Efficacy of Liposomal and Pegylated Liposomal Hydroxyurea

In Vitro Evaluation of the Efficacy of Liposomal and Pegylated Liposomal Hydroxyurea

Bioconjugated gold nanoparticles enhance cellular uptake: A proof of concept study for siRNA delivery in prostate cancer cells

Study of Toxicity Effect of Pegylated Nanoliposomal Artemisinin on Breast Cancer Cell Line

Contact Info

Product

Resources

About